[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

[1]  T. Wilt,et al.  Serenoa repens for benign prostatic hyperplasia. , 2012, The Cochrane database of systematic reviews.

[2]  T. Wilt,et al.  Microwave thermotherapy for benign prostatic hyperplasia. , 2012, The Cochrane database of systematic reviews.

[3]  M. Elhilali,et al.  Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial. , 2012, The Journal of urology.

[4]  T. Wilt,et al.  Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review , 2012, BJU international.

[5]  E. Vicaut,et al.  Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. , 2012, European urology.

[6]  N. Delongchamps,et al.  [Surgical management of benign prostatic hyperplasia by endoscopic techniques using electricity and open prostatectomy: A review of the literature by the LUTS committee of the French Urological Association]. , 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[7]  N. Delongchamps,et al.  Traitement chirurgical de l’hyperplasie bénigne de la prostate par thermothérapie et autres techniques émergentes : revue de littérature du CTMH de l’AFU , 2012 .

[8]  N. Delongchamps,et al.  Traitement chirurgical de l’hyperplasie bénigne de la prostate par laser : revue de littérature du CTMH de l’AFU , 2012 .

[9]  J. J. de la Rosette,et al.  Results from an international multicentre double‐blind randomized controlled trial on the perioperative efficacy and safety of bipolar vs monopolar transurethral resection of the prostate , 2012, BJU international.

[10]  V. Hernández,et al.  GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. , 2011, European urology.

[11]  T. Wilt,et al.  WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. , 2011, The Cochrane database of systematic reviews.

[12]  T. Wilt,et al.  Terazosin for benign prostatic hyperplasia. , 2011, The Cochrane database of systematic reviews.

[13]  A. Salonia,et al.  Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. , 2011, European urology.

[14]  John T. Wei,et al.  Update on AUA guideline on the management of benign prostatic hyperplasia. , 2011, The Journal of urology.

[15]  T. Tammela,et al.  Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. , 2011, European urology.

[16]  C. Chapple,et al.  Management of lower urinary tract symptoms in men: summary of NICE guidance , 2010, BMJ : British Medical Journal.

[17]  P. Abrams,et al.  Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. , 2009, European urology.

[18]  F. Montorsi,et al.  A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. , 2009, European urology.

[19]  A. De la taille,et al.  Laser treatment of benign prostatic hyperplasia in patients on oral anticoagulant therapy: a review , 2009, BJU international.

[20]  M. Deverill,et al.  Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. , 2008, Health technology assessment.

[21]  A. Skolarikos,et al.  Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. , 2008, Journal of endourology.

[22]  R. Armstrong,et al.  Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. , 2008, Mayo Clinic proceedings.

[23]  M. Elhilali,et al.  Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice , 2008, BJU international.

[24]  Jian Zhuo,et al.  Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. , 2008, European urology.

[25]  S. Yip,et al.  A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. , 2007, European urology.

[26]  M. Emberton,et al.  Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. , 2007, The Journal of urology.

[27]  C. Amling,et al.  Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. , 2007, The Journal of urology.

[28]  M. Emberton,et al.  Self-management for men with lower urinary tract symptoms , 2006, BMJ : British Medical Journal.

[29]  C. Roehrborn,et al.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.

[30]  J. Fitzpatrick.  The natural history of benign prostatic hyperplasia , 2006, BJU international.

[31]  S. Madersbacher,et al.  Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. , 2005, European urology.

[32]  G. Amarenco,et al.  Terminologie des troubles fonctionnels du bas appareil urinaire : Adaptation française de la terminologie de l’International Continence Society , 2004 .

[33]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[34]  P. Teillac,et al.  Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. , 2004, European urology.

[35]  A. Westenberg,et al.  Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum long-term followup. , 2004, The Journal of urology.

[36]  M. Emberton,et al.  Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. , 2004, European urology.

[37]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[38]  A. Bentivoglio,et al.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. , 2003, Urology.

[39]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[40]  A. Zlotta,et al.  Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. , 2003, European urology.

[41]  S. Madaan,et al.  5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. , 2003, Urology.

[42]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.

[43]  T. Peters,et al.  Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. , 2001, The Journal of urology.

[44]  T. Wilt,et al.  Laser prostatectomy for benign prostatic obstruction. , 2000, The Cochrane database of systematic reviews.

[45]  J H Wasson,et al.  5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. , 1998, The Journal of urology.

[46]  A. Tewari,et al.  Overview of α-Blocker Therapy for Benign Prostatic Hyperplasia , 1998 .

[47]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[48]  T. Wilt,et al.  Pygeum africanum for benign prostatic hyperplasia. , 1998, The Cochrane database of systematic reviews.

[49]  A L Gould,et al.  Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. , 1996, Urology.

[50]  N. Delongchamps,et al.  Traitement médical de l’hyperplasie bénigne de la prostate : revue de littérature par le CTMH/AFU , 2012 .

[51]  N. Delongchamps,et al.  [Initial assessment and follow-up of benign prostatic hyperplasia: systematic review of the literature by the LUTS committee of the French Urological Association]. , 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[52]  C. Roehrborn,et al.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.

[53]  S. Ahyai,et al.  Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. , 2008, European urology.

[54]  C. Roehrborn,et al.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. , 2005, Urology.